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Background: Despite the gradual improvement in treatment procedures and cure rates of acromegaly, a steady
increase in the mortality rate due to respiratory disease has been documented in recent decades. In this study, our
objectives were to describe the abnormalities in lung structure and function that occur in acromegalic patients and
to correlate these changes with hormonal levels.
Methods: This cross-sectional study included 20 acromegalic patients and 20 age-and height-matched control subjects,
all non-smokers. All subjects underwent spirometry, whole body plethysmography, carbon monoxide diffusing capacity,
and respiratory muscle strength. Acromegalic patients also performed high-resolution computed tomography (HRCT).
Results: Most patients were female (65%), with a mean age of 52.5 ± 13 years. Acromegalic patients showed lower
values of maximum expiratory pressure (55.9 ± 17.1 vs. 103.7 ± 19.2%; p < 0.001) and maximum inspiratory pressure
(71.4 ± 27.8 vs. 85.3 ± 24.1%; p = 0.005) compared to control subjects. The values of forced vital capacity (107.1 ± 15.9 vs.
98.9 ± 21.4%; p = 0.028), total lung capacity – TLC (107.3 ± 12.9 vs. 93.7 ± 7.60%; p = 0.002), residual volume (114.1 ± 22.7
vs. 90.0 ± 14.6%; p < 0.001), and airways’ resistance (3.82 vs. 2.31 cmH2O/L/s; p = 0.039) were greater in acromegalic
patients than in control subjects. The difference between the TLC measured by plethysmography and the VA (alveolar
volume) measured during the DLCO maneuver was higher in acromegalic patients than in control subjects (0.69 ± 0.46
vs. 0.19 ± 0.61 L; p = 0.021). The main findings in HRCT in acromegalic patients were air trapping, airway calcification
and bronchiectasis, which were observed in 60%, 40% and 35% of cases, respectively. There was no significant
correlation between the levels of growth hormone and insulin-like growth factor I, the lung function and the air
trapping.
Conclusions: Acromegalic patients show changes consistent with the involvement of the small airways and ventilation
inhomogeneity, both in terms of lung function and structure. However, air trapping cannot be explained either by
hormone levels or changes in lung function.
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Acromegaly is an endocrine disease that results from the
systemic consequences of excessive growth hormone (GH)
and insulin-like growth factor I (IGF-I). Its prevalence is
approximately 60 cases per million inhabitants, while the
incidence is estimated at 3 to 4 cases per million people* Correspondence: agnaldolopes.uerj@gmail.com
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reproduction in any medium, provided the or[1,2]. Patients with acromegaly show a relative risk of mor-
tality from respiratory disease 1.85 times higher than in
general population [3]. Excess GH may lead to severe sys-
temic manifestations, including orthopedic, cardiovascular,
and respiratory problems [4,5].
The mortality rate due to respiratory disease is ap-
proximately three times higher in acromegalic patients
than in healthy subjects, and respiratory problems also
contribute to approximately 25% of all deaths found in
this group of patients [3,6-9]. Patients with acromegaly
develop various respiratory disorders resulting from ana-
tomic distortion of soft tissues, cartilage, muscles, andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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produces two primary respiratory alterations, known as
obstructive sleep apnea and impaired respiratory func-
tion [7,10,11].
In acromegaly, the mechanical changes in the respira-
tory system elastance and the changes in the geometry of
respiratory muscles may potentially lead to lung diseases.
In these patients, the respiratory muscle strength is al-
tered, the inspiratory time is shortened, the respiratory
rate may increase, and subclinical hypoxemia may be
present [12]. Despite these alterations, few studies have
studied pulmonary function in acromegalic patients [13].
Several studies in acromegalic patients have shown
bone and cartilage alterations involving the upper air-
ways and chest wall structures. The axial skeleton is
affected in up to 60% patients and includes the thicken-
ing of soft and cartilaginous tissues, enlargement of
the intervertebral spaces, formation of osteophytes, and
kyphoscoliosis [14-16]. The changes in the upper airways
and chest wall in acromegaly are already well docu-
mented using imaging methods. However, to our know-
ledge, no research has been conducted to detect lung
abnormalities using high-resolution computed tomog-
raphy (HRCT) in acromegalic patients. Moreover, ex-
piratory computed tomography (CT) has been proposed
as a good method for early diagnosis of the involvement
of the small airways in systemic diseases [17,18].
Although acromegaly is well studied in the context of
cardiovascular, metabolic and musculoskeletal disorders,
there is still much controversy regarding the changes oc-
curring in the lungs. The use of HRCT and pulmonary
function tests may provide key data on possible pulmon-
ary changes that occur in acromegaly. Thus, our objectives
were to describe the abnormalities in lung structure and
function in acromegalic patients and to correlate these
changes with hormonal levels.
Methods
Patients
This cross-sectional study was conducted between June
2012 and March 2013. The study involved 26 subjects
with acromegaly (age >18 years) who were followed up
at the Clementino Fraga Filho University Hospital of the
Federal University of Rio de Janeiro. Diagnoses were
based on clinical features and were confirmed by high
levels of GH that did not fall below 0.4 ng/mL after an
oral glucose tolerance test or IGF-I levels above the
upper limit of the age-specific normal range [19,20].
Patients were considered to have controlled acromegaly
when their IGF-I levels were within the age-adjusted refer-
ence range and when their baseline GH level was less than
1.0 ng/mL [20]. Patients with a history of smoking and pa-
tients with comorbidities unrelated to acromegaly that
could interfere in the pulmonary function testing were notincluded in the study. Untreated hypothyroidism and
hypocortisolism were also considered as exclusion criteria.
A control group of 20 healthy volunteers of both genders
was recruited from the Augusto Motta University Center
(UNISUAM). These individuals did not exhibit any history
of smoking or evidence of cardiorespiratory disorder.
All participants signed an informed consent form, and
the protocol was approved by the Research Ethics Com-
mittee of the State University of Rio de Janeiro under
number 234.362.
Measurements
The serum concentrations of GH and IGF-I were routinely
measured using commercial two-site chemiluminescen-
ceimmunometric assays (Immulite, Diagnostic Product
Corporation, Los Angeles, CA, USA). The IGF-I level was
assayed by IRMA after ethanol extraction of binding pro-
teins (Diagnostic Systems Laboratories, Webster, TX,
USA). The percentage of values that exceeded the age-
adjusted normal value of IGF-I (upper limit normal value -
ULNV) was calculated, and zero was assigned for normal
dosages.
The pulmonary function testing consisted of spirom-
etry, body plethysmograph, carbon monoxide diffusing
capacity (DLCO), and respiratory muscle strength. Mea-
surements were conducted using an HD CPL (nSpire
Health, Inc., Longmont, CO, USA), following standard
procedures and interpretation [21]. The pulmonary func-
tion testing results were expressed as a percent of the
predicted values for the Brazilian population [22-25].
Percent of the predicted values outside of the lower limit
of normal (LLN) or upper limit of normal (ULN) were
considered abnormal. An obstructive ventilatory defect
was defined by a forced expiratory volume in 1 second
(FEV1)/forced vital capacity (FVC) ratio < LLN [26].
The CT images were recorded in a helical CT scanner
with 64 channels (Brilliance 40, Philips Medical Systems,
Cleveland, OH, USA). The readout time was set to 4 s,
with an X-ray tube current of 458 mA and voltage of
120 kVp. Each image acquisition consisted of a block
with 250 to 400 2-mm-thick cross sections separated by
1 mm. The images were represented by a square matrix
of 768 rows and 768 columns and were recorded with-
out gantry tilt. In all subjects, both end-inspiratory and
end-expiratory scans were obtained. Iodinated contrast
agent was not used in any of the examinations. The
HRCT scans were interpreted by the consensus of two
chest radiologists (R.M. and G.B.C.).
Data analysis
The data distribution was tested using the Shapiro-Wilk
test. Comparisons were made using a t-test or Mann–
Whitney test. Pearson or Spearman correlation tests
were used to assess the associations between variables.
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deviation or frequencies (percentage). The analyses were
performed using the software SigmaStat 3.5 (Systat Soft-
ware, San Jose, CA, USA). The statistical significance
was set at p < 0.05.
Results
Six out of the 26 initially recruited acromegalic patients
were excluded for the following reasons: refusal to par-
ticipate in the study (4) and inability to reach the accept-
ability criteria in pulmonary function tests (2). Thus, the
acromegalic group included 13 women and seven men
with a mean age of 52.5 ± 13 years. Four patients (20%)
had hypopituitarism, although they were undergoing
hormone replacement therapy and had normal hormone
levels. Fifteen patients (75%) underwent surgery and five
patients (25%) underwent radiation therapy. As to the
pulmonary function, an obstructive ventilatory defect
was diagnosed in 40% of the cases. The total lung cap-
acity (TLC) and the residual volume (RV) were > ULN in
15% and 30% of the cases, respectively. Conversely, an
RV/TLC ratio > ULN was noted in 40% of the patients.
The acromegalic patients’ laboratory data and general
characteristics are shown in Table 1.
The control group (15 women and five men) had the
following anthropometric characteristics: age = 50.9 ±
15.7 years; height = 162 ± 0.09 cm; weight = 71.3 ± 9.94 kg;
BMI = 27.2 ± 3.34 kg/m2. There were no significant differ-
ences between healthy volunteers and patients with acro-
megaly regarding age (p = 0.73) and height (p = 0.35). The
weight and BMI significantly differed between the two
groups (p < 0.001 for both).
Tables 2 and 3 show the comparisons of the pulmonary
function parameters between the healthy volunteers and
the acromegalic patients (absolute values and percent pre-
dicted values). There were statistically significant differ-
ences between the values of maximal inspiratory pressureTable 1 General characteristics and laboratory data of 20
acromegalic patients
General characteristics
Age (years) 52.5 ± 13
Gender (female), n (%) 13 (65)
Height (cm) 165 ± 0.10
Weight (kg) 85.8 ± 11.5
BMI (kg/m2) 31.7 ± 4.02
Time since diagnosis of disease (months) 101.7 ± 42.6
Laboratory data
GH (μg/L) 2.81 ± 2.78
IGF-I (μg/L) 416.5 ± 290.9
IGF-I (% ULNV) 171.8 ± 115.7
Values are means ± SD or numbers (%). BMI, body mass index; GH, growth
hormone; IGF-I, insulin-like growth factor I; ULNV, upper limit normal value.(MIP), maximal expiratory pressure (MEP), FVC, TLC,
RV, and airways resistance (Raw). The difference between
the TLC measured by plethysmography and the alveolar
volume (VA) measured during the DLCO maneuver (TLC-
VA difference) was also statistically different between the
two groups.
In the group of acromegalic patients, 55% had active
disease, while 45% had controlled disease. Although the
patients with active disease showed higher mean pul-
monary function values in all variables except RV/TLC,
no significant differences were found in absolute and
percent predicted values between the groups (p > 0.05
for all comparisons).
There was no association between the values of GH,
IGF-I (μg/L), and IGF-I (% ULNV) hormone levels and
the pulmonary function parameters when using either
absolute or percent predicted values (p > 0.05 for all).
The main HRCT findings are shown in Table 4. The
main change was air trapping (60% of cases), which was
diffuse in 20% of the patients (Figures 1 and 2). When
sparse, air trapping was mainly detected in the lower
lobes. Other common abnormalities included airway cal-
cification (40% of cases) (Figure 3) and bronchiectasis
(35% of cases) (Figure 1).
No significant difference was found between the mean
values of time since disease diagnosis, GH, IGF-I (μg/L),
IGF-I (% ULNV), and pulmonary function parameters
(absolute values and percent predicted values) when
comparing the two groups according to the presence or
absence of air trapping in HRCT.
Discussion
Our study shows that acromegalic patients present with
impaired pulmonary function, namely increased static
lung volumes, increased TLC-VA difference, and aug-
mented Raw. As to the imaging, air trapping is the most
common alteration in those patients. In the lungs, the
changes in the structure and function mainly affect the
lower airways. To date, no study has focused on this
issue in a sample of nonsmoking patients without pul-
monary comorbidities.
In the present study, pulmonary function results of the
two groups were compared both in absolute values and
in percent predicted values. Since acromegalic patients
tend to present higher values of body weight, body cell
mass and extracellular water [27], we consider that the
comparison is best seen as percent of predicted values
[21]. We observed an increase in FVC (107.1 ± 15.9 vs.
98.9 ± 21.4%; p = 0.028), TLC (107.3 ± 12.9 vs. 93.7 ±
7.60%; p = 0.002), and RV (114.1 ± 22.7 vs. 90.0 ± 14.6%;
p < 0.001) in acromegalic patients compared with the
control group. The cause of increased static lung vol-
umes in acromegaly has been discussed in the literature.
Some studies indicate increased alveolar size [13,28],
Table 2 Pulmonary function test results in healthy volunteers and acromegalic patients (absolute values)
Control group (n = 20) Acromegaly group (n = 20) p
FVC (L) 3.27 ± 0.85 3.67 ± 1.03 0.186
FEV1 (L) 2.60 ± 0.65 2.92 ± 0.79 0.168
FEV1/FVC (%) 84.7 ± 3.25 79.8 ± 4.11 0.598
FEF25-75% (L/s) 2.61 ± 0.71 3.08 ± 1.16 0.130
FEF25-75%/FVC (%) 79.4 ± 6.06 83.6 ± 7.93 0.605
MIP (cm H2O) −81.3 ± 29.4 −63.6 ± 28.9 0.063
MEP (cm H2O) 121 ± 32.9 92.3 ± 30.79 0.001
TLC (L) 4.83 ± 0.98 5.61 ± 1.09 0.023
RV (L) 1.55 ± 0.32 2.04 ± 0.38 <0.001
RV/TLC (%) 32.6 ± 6.89 37.5 ± 8.94 0.063
Raw (cm H2O/L/s) 2.31 ± 0.58 3.82 ± 0.49 0.039
DLCO (ml/min/mm Hg) 22.6 ± 5.66 23.3 ± 6.46 0.713
VA (L) 4.61 ± 1.33 4.92 ± 1.19 0.443
DLCO/VA (ml/min/mm Hg/L) 5.08 ± 1.06 4.72 ± 0.64 0.205
TLC-VA difference (L) 0.19 ± 0.61 0.69 ± 0.46 0.021
Values are means ± SD or numbers (%). DLCO, diffusing capacity for carbon monoxide, FEF25-75%, forced expiratory flow during the middle half of the FVC;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; Raw, airway resistance;
RV, residual volume; TLC, total lung capacity; VA, alveolar volume.
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[29,30]. García-Río et al. [13] noted that the increased lung
compliance and reduced lung recoil pressure found in pa-
tients with acromegaly were minimized following hormo-
nal control. These data make it unlikely that an increased
number of alveoli could explain the increase in lung vol-
ume; thus, it would be more plausible to assume an in-
crease in alveolar size in patients with acromegaly.
In the healthy subjects, the VA is essentially the same
as the TLC (± 200 mL) and can be used as an estimateTable 3 Pulmonary function test results in healthy volunteers
Control group (n = 20)
FVC (% predicted) 98.9 ± 21.4
FEV1 (% predicted) 96.2 ± 11.9
FEV1/FVC (% predicted) 97.2 ± 3.30
FEF25-75% (% predicted) 91.5 ± 18.9
FEF25-75%/FVC (% predicted) 95.2 ± 6.77
MIP (% predicted) 85.3 ± 24.1
MEP (% predicted) 103.7 ± 19.2
TLC (% predicted) 93.7 ± 7.60
RV (% predicted) 90.0 ± 14.6
RV/TLC (% predicted) 94.9 ± 13.4
DLCO (% predicted) 103.1 ± 13.9
VA (% predicted) 90.5 ± 15.5
DLCO/VA (% predicted) 116.4 ± 22.3
Values are means ± SD or numbers (%). DLCO, diffusing capacity for carbon monoxid
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEP, maxima
RV, residual volume; TLC, total lung capacity; VA, alveolar volume.of TLC [31]. In the present study, the TLC-VA differ-
ence was higher in acromegalic patients than in control
subjects (0.69 ± 0.46 vs. 0.19 ± 0.61 L; p = 0.021). Inter-
estingly, the TLC-VA difference provides an estimate of
the severity of nonuniform gas distribution, that is the
volume of poorly ventilated lung [31,32]. Thus, it may
result from large trapped-gas regions in acromegalic pa-
tients. It is noteworthy that the TLC-VA difference in
patients with air trapping was higher than in those
without air trapping on HRCT despite the absence ofand acromegalic patients (% predicted values)
Acromegaly group (n = 20) p
107.1 ± 15.9 0.028
104.8 ± 15.5 0.057
94.0 ± 4.86 0.572
105.9 ± 20.1 0.261
99.4 ± 7.05 0.630
71.4 ± 27.8 0.005
55.9 ± 17.1 <0.001
107.3 ± 12.9 0.002
114.1 ± 22.7 <0.001
107.1 ± 27.2 0.068
103.7 ± 24.4 0.968
93.6 ± 12.2 0.147
110.2 ± 18.5 0.346
e, FEF25-75%, forced expiratory flow during the middle half of the FVC;
l expiratory pressure; MIP, maximal inspiratory pressure; Raw, airway resistance;
Table 4 Abnormalities on chest computed tomography in
patients with acromegaly




Ground-glass opacity 4 (20)
Airway calcification 8 (40)
Trachea 6 (30)
Main bronchus 5 (25)
Values are number of cases (%).
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p = 0.268).
We noted an increase in Raw (3.82 ± 0.49 vs. 2.31 ±
0.58 cm H2O/L/s; p = 0.039) in our sample of acromegalic
patients compared with the control subjects, in addition
to increased RV. The acromegalic patients also showed
higher RV/TLC than the control subjects despite the ab-
sence of a statistically significant difference (107.1 ± 27.2
vs. 94.9 ± 13.4%; p = 0.068). Interestingly, abnormalities in
acromegalic patients’ lower airways have already been in-
vestigated by some authors [10,11]. Harrison et al. [10]
noted an increase in Raw in 14 out of 30 acromegalic pa-
tients. According to these researchers, the narrowing of
small airways can be attributed to vascular congestion of
the surrounding lung or even to the accumulation of soft
tissues around the small airways. Conversely, Trotman-
Dickenson et al. [11] detected lower airway obstruction in
eight out of 35 patients. However, both the study by
Harrison et al. [10] and that by Trotman-Dickenson et al.
[11] included smokers and did not use a control group.
Another possible explanation for the involvement of
small airways in acromegalic patients is the excessive lung
growth because the terminal flows largely depend on lung
volume and airways size, and these two variables are inter-
related – a phenomenon known as dysanapsis [33,34]. InFigure 1 Bronchiectasis and air trapping in a 56-year-old man with ac
value of 5.23 cm H2O/L/s. (a) Inspiratory, transverse, thin-section CT scan
(b) Expiratory, transverse, thin-section CT scan obtained through the lowerthe present study, however, the mean value of the forced
expiratory flow during the middle half of the FVC
(FEF25-75%)/FVC ratio (a measure to estimate dysa-
napsis) [33] is greater in acromegalic patients than in
control subjects despite the absence of statistical signifi-
cance (99.4 ± 7.05 vs. 95.2 ± 6.77%; p = 0.630). There-
fore, it is possible that the highest Rwa in acromegalic
patients may only be explained by a loss of elastic tissue
of alveoli and small airways.
Acromegaly also affects the function of respiratory mus-
cles [8]. In fact, studies with muscle biopsy have shown
segmental muscle fiber degeneration, foci of cellular infil-
tration, and variable breakdown in both type I and II fibers
[35]. We also observed a significant reduction in MEP and
MIP values in acromegalic patients compared to normal
subjects (55.9 ± 17.1 vs. 103.7 ± 19.2%, p < 0.001; 71.4 ±
27.8 vs. 85.3 ± 24.1, p = 0.005; respectively), corroborating
the study by Iandelli et al. [36].
Similarly to other studies [13,37], we also failed to find
significant correlation between the level of GH and pul-
monary function. In contrast to animal models, no GH
binding site has been found in human lungs thus far.
This result suggests that this hormone does not play a
direct physiological role in alveolar development and
growth [38], which could explain our inability to demon-
strate any statistically significant correlation.
Alterations in HRCT have not been previously studied
in acromegalic patients. Our study showed the high fre-
quency of air trapping (60%) and bronchiectasis (35%).
This finding reinforces the notion that the lower airways
are somewhat compromised in these patients. Air trapping
is induced by narrowing of airways [18] and is associated
with bronchiectasis in some cases [39]. Air trapping, when
diffuse (which occurred in 20% of our sample) is always
associated with some type of pathological alteration, al-
though it may also be found in healthy subjects [18,40,41].
In the present study, we did not observe significant corre-
lations between air trapping and pulmonary functionromegaly who had an RV value of 126% of predicted and a Raw
obtained through the lower lung zone shows bronchiectasis (arrows).
lung zone reveals diffuse air trapping (arrowheads).
Figure 2 Air trapping in a 57-year-old man with acromegaly who had a RV value of 173% of predicted and a Raw value of 3.47 cm
H2O/L/s. (a) Inspiratory, transverse, thin-section CT scan obtained through the lower lung zone shows no abnormal findings. (b) Expiratory,
transverse, thin-section CT scan obtained through the lower lung zone reveals diffuse air trapping (arrows).
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ment basic evaluations to detect small airways disease in
acromegalic patients.
Are there similarities between the ‘acromegalic lung’
and the ‘senile lung’ from the anatomo-physiological
standpoint? Microscopically, lung aging is marked by
dilatation of alveoli without signs of destruction of the
septa or obvious inflammation [42,43]. In acromegalic
patients an increase in alveolar size presumably occurs
due to changes in the elastic properties of the lungs, des-
pite the lack of histopathological studies [8,13]. In the
elderly, there is increased lung compliance and de-
creased elastic recoil pressure [44,45]. These findings are
also reported in acromegalic patients [13]. The loss of
elasticity with aging, along with the loss of support of
the small airways, leads to a gradual reduction in the
rate of lung emptying [46]. A similar phenomenon pre-
sumably also occurs in acromegalic patients, causing
changes in the small airways [10,11]. Interestingly, these
findings have also been reported in the HRCT of healthy
elderly [18,47], similarly to the high frequency of air
trapping and bronchiectasis that we have shown in the
population of acromegalic patients. Lee et al. [18] found
air trapping areas in 76% of subjects aged 61 years or
older and also noted a statistically significant correlation
between air trapping and age (r = 0.523; p < 0.001).Figure 3 Airway calcification in a 49-year-old woman with acromegal
2.95 cm H2O/L/s. (a) Axial unenhanced CT scan (mediastinal window) sho
(mediastinal window) shows bronchial calcifications (arrows).These authors believe that occlusion or luminal narrow-
ing of the airways associated with age may occur at the
level of the secondary pulmonary lobule, causing the
appearance of air trapping areas. It is noteworthy that
airway calcification is a finding that appears in both
acromegalic patients and elderly [48]. The changes that
occur in lung tissues may at least partly explain the link
between the ‘acromegalic lung’ and the ‘senile lung’. In
lung tissue, GH is able to increase the synthesis of colla-
gen type I fibers and mucopolysaccharides [49]. Studies
in the elderly show a possible reduction of the amount
of elastic fibers in the lung parenchyma and a possible
increase in collagen, mainly type III collagen [50].
A critical analysis of the results is warranted. Firstly, we
didn’t do more refined measurements for the assessment
of small airways, including nitrogen washout. These mea-
surements could give greater support to our hypothesis of
early lung aging in acromegalic patients. Secondly, we did
not measure the static recoil pressure that would allow a
greater understanding of respiratory mechanics in these
patients. Thirdly, a pairing with a control group in terms
of weight and BMI could help in the interpretation of lung
function. Some acromegalic patients were obese, which
may have also decreased their lung volumes by reducing
respiratory system compliance, precluding finding larger
differences with healthy controls. Fourthly, the absence ofy who had an RV value of 120% of predicted and a Raw value of
ws tracheal calcifications (arrows). (b) Axial unenhanced CT scan
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Committee), does not allow us to say that the finding of
air trapping is characteristic of acromegaly. Notwithstand-
ing these limitations, our results indicate the involvement
of the lower airways (not just the upper airways) in acro-
megalic patients, and this involvement was expressed both
in terms of lung function and structure. Thus, this study
may serve as a starting point for future anatomical and
physiological studies assessing the changes in the lower
airways of these patients, including the comparison among
active disease, controlled disease and healthy controls in a
more robust sample.
Conclusions
In conclusion, the present study shows that acromegalic
patients have abnormalities consistent with the involve-
ment of the small airways and ventilation inhomogeneity,
both in terms of lung function and structure. However,
the air trapping detected by HRCT cannot be explained ei-
ther by hormone levels or changes in lung function.
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